Register Now for the Launch Event

On January 25, 2021


From the original notion of monoclonal antibodies as “magic bullets” right through to the latest generation of COVID-19 vaccines, stem cell therapies and exosomes, cell line development is experiencing a rapid expansion in both scope and output of novel biotherapeutics. Clonality, and the gathering of quality evidence, has been central to cell line development for the last decade, and with it, driving the rise of high-caliber seeding and imaging technologies.

In this informative webinar, market leader Solentim will introduce two new products, an instrument named ICON™, that is designed to empower laboratories to make better decisions faster, and an over-arching software platform called STUDIUS™.

Learn about how these two new products work to provide a new data-driven workflow for the development of modern cell-based therapies.

Participants will be hearing from Solentim’s R&D and biology groups alongside cell line development experts in this first insight into Solentim’s new products.

Register for this webinar to view the presentation, with the opportunity to ask the development team about the capabilities of these new systems.




Yes, I’m OK with this



Duncan Borthwick PhD, Global Marketing Manager, Solentim

Duncan Borthwick has a PhD from the University of Edinburgh and University of North Carolina, Chapel Hill Since hanging up his lab coat 20+ years ago, Duncan has worked in the development of novel instrumentation and products. He heads the Product Management group at Solentim working closely with the R&D, biology and commercial teams working to define the next set of products to support the cell therapy community.


Mark Stockdale, Galvanize Bio

Mark Stockdale is a keen technology consultant. He worked as a Group Leader at Horizon Discovery Ltd, a scientist within Lonza Biologics, Cyclacel Ltd and started his career at Pfizer. With over 15 years of professional experience in cell line development and drug discovery, his passion is to bring new technologies to bear on unmet needs and provides great insight into the future technology requirements in stable cell line development.